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 1
 Introduction 
In the accompanying Perspective, Cryer identifies a number of different areas where 
therapeutic interventions have the potential to reduce hypoglycemia without 
compromising glycemic control.  Some approaches provide well defined clinical benefits, 
a few offer dramatic reductions in hypoglycemia but remain out of reach for most people 
while others, although promising have yet to be properly evaluated.  (Table 1) 
In this Perspective, I examine the evidence which underpins these interventions.  It is 
beyond the scope of this article to review the data for each potential intervention in detail 
but the reader is directed to the appropriate source where appropriate.  The Perspective 
focuses on treatment of Type 1 diabetes as most of the potential specific therapies have 
been evaluated in this group although I have commented in relation to recent trials of 
intensive therapy in Type 2 diabetes.  
Preventing absolute or relative insulin excess 
Education and Skills training in self management 
Long before the benefits of tight glucose control had been established,(1) the belief that 
insulin therapy should be designed to replace insulin “physiologically” had been 
advocated by a small number of enthusiastic clinicians. The advent of blood glucose 
monitoring in the late 1970s had a major impact since background and meal related 
insulin could be given separately and adjusted according to self-monitored blood glucose 
measurements. Participants were encouraged to eat freely, calculating their insulin dose 
according to their chosen amount of carbohydrate.   
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Integrating these components was a complex task, probably beyond that of many 
physicians, let alone patients.  If this was to be undertaken every day then patients needed 
to acquire the skills of flexible insulin self management and apply it successfully.  The 
therapeutic education approach was pioneered by Assal and colleagues,(2) and Berger 
and Mühlhauser went on to develop a residential training course (Insulin Treatment and 
Training programme, ITTP), evaluating the intervention in a series of studies, including 
randomised controlled trials.(3)  Their group highlighted the major differences between 
rates of severe hypoglycemia in different centres in the DCCT and suggested that these 
might have reflected a failure to train patients to undertake intensive self-management 
safely.(4)   
Their data which include a large evaluated roll-out suggest that it is possible to improve 
and sustain glycemic control, comparable to the DCCT using conventional insulin while 
reducing rates of severe hypoglycemia. (Figure 1) (5; 6)  Different definitions of 
hypoglycemia prevent a detailed comparison between these and other studies but their 
principle argument that no-one should embark on intensive insulin therapy and aim for 
tight glucose targets without acquiring appropriate self management skills is compelling.  
Even in countries where such training is relatively established,(6; 7) relatively few adults 
with Type 1 diabetes appear to have undertaken validated courses in intensive insulin 
self-management.   
Other programs have been developed to train patients specifically to recognise both high 
and low glucose values although most interest has centred around their ability to identify 
impending hypoglycemia.  Blood glucose awareness training (BGAT) developed by Cox 
and colleagues at the University of Virginia(8) seeks to train patients with Type 1 
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diabetes to improve estimation of their blood glucose based on recognition of external 
cues and the known pathophyiological changes associated with autonomic and 
neuroglycopenic responses to hypoglycemia.  Participants also receive feedback on their 
glucose estimations. The approach shares several features with the ITTP training of the 
Düsseldorf group and has also been extensively evaluated.  Trials led by the investigators 
have demonstrated prevention of a blunted counterregulatory response during 
intensification of insulin therapy(9) and an improved ability to estimate blood glucose 
which is maintained over some years with fewer severe hypoglycemic events.(10)  
In summary, there is a reasonable body of evidence demonstrating that high quality skills 
training in insulin self management involving accredited educators leads to improved 
glycemic control without increasing severe hypoglycemia.  Specific programmes appear 
particularly beneficial to those with hypoglycemic problems.  
Improved insulin delivery in routine care 
The limitations of subcutaneous insulin delivery have been well recognised ever since its 
discovery.  The intermittent injection of insulin into subcutaneous tissue produces insulin 
profiles which, while able to control blood glucose sufficiently to relieve symptoms and 
prevent ketosis are far from physiological.  The advent of recombinant DNA technology 
in the 1980s prompted the pharmaceutical industry to engineer different structures of the 
insulin molecule to address the limitations of subcutaneous insulin delivery.(11) 
The tendency of insulin molecules of conventional animal structure to aggregate in 
crystalline solution delays its absorption. Transposing or substituting amino acids 
produces insulins with less tendency to self aggregate. (12)  The molecules remain 
monomeric at high concentration and their more rapid absorption results in a more 
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physiological insulin profile.  Yet the clinical advantages of quick acting insulin analogs 
over conventional insulin have generally been modest in clinical trials, both in lowering 
HbA1c and hypoglycemia and some have concluded that they offer little additional 
benefit.(13) Nevertheless, there is reasonable evidence reporting reduced nocturnal 
hypoglycemic risk when using rapid acting insulin analogs in those with well controlled 
Type 1 diabetes,(14; 15) an outcome not included in the recent Cochrane review.(13) 
The other main pharmacokinetic limitation of conventional insulin delivery has also been 
addressed.  Human NPH insulin, exhibits considerable inter- and intra-individual 
variability in part due to the necessity of re-suspension before injection.  This, plus a 
pronounced peak of action around 6-8h after injection contributes to the risk of nocturnal 
hypoglycemia.  Insulin manufacturers have tried to solve these problems in ingenious 
ways.  Insulin glargine (Lantus), a di-arginyl insulin analog is a soluble insulin at an acid 
pH and then crystallises in the more alkaline subcutaneous environment.(12)  Insulin 
detemir (Levemir) has been constructed by adding a myristoyl fatty acid side chain at the 
C terminus of the B-chain which causes the insulin to bind to albumin.(12)  Both insulins 
have a more prolonged action than NPH and a reduced peak and provide a more 
physiological free insulin profile with the potential to lower rates of hypoglycemia.  Yet, 
as with rapid acting insulin analogs the major pharmacokinetic differences compared to 
NPH insulin are not in general, reflected in the clinical trial data.   
Benefits of long acting insulin analogs have been modest in both types of diabetes with 
little if any difference in glycemic control and only slight reductions in hypoglycemia, 
mostly at night.(16)  The combination of both long and short acting insulin analogs leads 
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to significant albeit minor reductions in both HbA1c and hypoglycemia in adults with 
Type 1 diabetes.(17; 18)  
A major difficulty in interpreting the mountain of data around insulin treatment is that the 
limitation of its delivery is just one of many factors determining glycemic control and the 
risk of hypoglycemia.  Thus, regulatory clinical trials may underestimate the potential 
benefit since they rarely recruit highly motivated individuals who are expert at self-
managing their diabetes and can best utilise the pharmacokinetic advantages. Regulatory 
trials may also favor conventional insulins since clinical experience with the newer 
insulins is often necessary to establish the most effective combination and timing of 
injection.  However, since asymptomatic nocturnal hypoglycemia may contribute to the 
generation of hypoglycemia unawareness(19) such insulins should be offered to those 
skilled in insulin self management who are experiencing hypoglycemic problems. 
 
Continuous subcutaneous insulin infusion 
The limitations of long acting insulins have driven the increasing use of continuous 
subcutaneous insulin infusion (CSII) as a realistic treatment option for many, at least in 
wealthy countries.  The approach is now used by over 20% of individuals with Type 1 
diabetes in the USA.(20)  CSII is the most effective, generally available method of 
insulin delivery although subcutaneous administration plus the continued need for 
frequent adjustments of infusion rates according to intermittent SMBG is hardly 
physiological.  The need to justify reimbursement of the increase in costs has resulted in a 
substantial number of trials and systematic reviews. The most recent, which include trials 
involving more modern devices, report falls in HbA1c of around 0.6-0.4% with no 
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increase in hypoglycemia; advantages confined to adults with Type 1 diabetes.(21; 22)  
There were insufficient data to establish benefit in children and no advantage of CSII in 
Type 2 diabetes. Few groups have undertaken a formal meta-analysis of hypoglycemic 
outcomes due to different definitions and potential bias due to lack of blinding when 
judging endpoints.  
Observational studies report greater reductions in HbA1c and severe hypoglycemia but 
are inevitably prone to bias since only those who experience benefit are likely to continue 
using the approach.  Furthermore the use of CSII is a complex intervention, involving not 
only the pump but also instruction in carbohydrate counting and insulin adjustment 
within a structured training programme.  Thus, part of the benefit of pump therapy may 
relate to the training that accompanies it.  Few trials have apparently controlled for the 
training element and reported falls in rates of severe hypoglycemia are similar to those 
reported for self-management training using multiple injections.   
Nevertheless, it seems clear that for highly motivated individuals with the ability to self-
manage their diabetes effectively, modern CSII technology can improve glycemic control 
without increasing hypoglycemia.  If acceptable to the patient, it should also be part of a 
package for patients experiencing problems with hypoglycemia.  
Preventing insulin excess for the few, implantable pumps, pancreas and 
islet transplantation 
There are a number of interventions which have been reported to have major effects in 
reducing hypoglycemia.  The use of implantable pumps with specially designed pumps 
housed within the subcutaneous tissue of the abdominal wall and insulin delivered into 
the peritoneum have been pioneered by a group in France.  Clinical experience is 
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relatively limited at around 350 patient-years but the investigators have reported major 
reductions in severe hypoglycemia, impressive HbA1c concentrations and improved 
quality of life.(23)  Evaluation of such therapy is largely based on observational studies 
although some randomised trials have been undertaken.  Catheter blockage is a 
continuing problem and after over 15 years experience the approach has not entered 
mainstream clinical care.  It would not appear to be a realistic treatment option for most 
adults with diabetes in the foreseeable future.  
The limitations of current insulin delivery are emphasised by the dramatic effect that 
pancreas transplantation has in curing the problems of hypoglycemia.  Whole pancreas 
transplantation leads to insulin independence in the short and medium term and the 
resolution of hypoglycemia unawareness at the expense of considerable perioperative 
morbidity and occasional mortality.  The results of whole pancreas transplantation have 
improved in recent years with 80% graft survival at 5 years and it is now approved as a 
treatment for severe hypoglycemic instability.(24)   
Islet cell transplantation is less invasive but results in less preservation of insulin 
secretion;  a recent report from specialist North American centres indicates that under 
10% of recipients are insulin free at 2 years.(25)  Nevertheless, around 70% of 
individuals had detectable C-peptide, of whom none were experiencing their previous 
difficulties with hypoglycemia unawareness.   
Both treatments are accompanied by the hazards of prolonged immunosuppression with 
increased risks of infection and malignancy.  Add to this the current shortage of donor 
tissue and it is clear that although this treatment has moved from an experimental to a 
clinical treatment in some countries and cures even severe hypoglycemia unawareness, it 
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is not an option for most individuals with Type 1 diabetes, either now or in the medium to 
longterm.  Nevertheless, pancreas or islet transplantation should be considered for 
patients with profound problems with hypoglycemia in those areas where it is available 
and when other treatments have failed.   
Alerting patients to impending hypoglycemia 
Continuous glucose monitoring  
Continuous glucose monitoring technology has now been available for over 10 years and 
each year sees further development and refinement; devices now on the market can 
provide readings in ‘real time’ plus the ability to alert patients to a falling glucose.  Early 
studies highlighted the ability of devices to identify unsuspected nocturnal 
hypoglycemia(26) but reports of ‘hypoglycemia’ in non diabetic individuals and disparate 
values registered by two similar devices attached simultaneously to the same person led 
to a reappraisal of their ability to identify hypoglycemia reliably.(27)  The problems are 
not purely technological.(28)  Even if the equipment records glucose concentrations fast 
and accurately, measurements will inevitably differ from blood glucose due to: 
1) the need for calibration with blood glucose.  A failure to ensure this is undertaken 
at steady state will introduce error. 
2) the physiological differences between values measured in the sc tissue (interstitial 
glucose) and blood glucose.     
Thus, ‘real time’ devices may be of more use when providing information about the 
change in glucose rather than absolute values.  Continuous glucose monitoring can 
identify unsuspected low glucose values, particularly at night which might contribute to 
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the generation of hypoglycemia unawareness.  Yet this cannot overcome the difficulty of 
adjusting imperfect insulin delivery systems in an attempt to prevent insulin excess.  
The real immediate potential lies in their use as a hypoglycemia alarm, yet years after the 
first introduction of such devices, few individuals with Type 1 diabetes are using them 
regularly.  There will always be a trade-off between sensitivity and specificity but at 
present, specificity is insufficient,(29) perhaps in part due to differences between 
interstitial and blood glucose.(28)  The need to replace sensors at relatively short 
intervals, the greater accuracy in the high rather than the low glucose range and the 
difficulty in arousing patients from sleep during nocturnal hypoglycemic episodes 
emphasise the hurdles still to be overcome.  An independent group recently concluded 
that none of the current devices performed reliably enough to be recommended as 
hypoglycemia alarms.(30) 
Observational studies have reported reductions in severe hypoglycemia but in the absence 
of a control group it is unclear whether this fall was entirely due to the provision of the 
device. Randomised controlled trials have generally shown modest advantages in 
surrogate endpoints such as the time spent in the normoglycemic range.(28)  Whether this 
translates into a reduced risk of severe hypoglycemia is unclear as most studies are 
underpowered due to insufficient numbers of patients.  A recent systematic review found 
that the use of continuous monitoring did not reduce HbA1c but there was a suggestion 
that episodes of nocturnal hypoglycemia were reduced. (31)  Unfortunately the 
heterogeneity of the studies, largely due to different definitions of hypoglycemia made it 
impossible to increase statistical power by pooling the data.  It is important that 
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investigators agree a common definition of hypoglycemia to allow the future use of 
metanalyses to analyse future trials.  
In the absence of a reliable alarm, as Wolpert has highlighted,(32) the potential of 
continuous glucose monitoring  to reduce hypoglycemia will depend upon the ability of 
patients to combine the information obtained with adjustments to their insulin and eating 
habits.  This needs an active interest in self-management plus a good working knowledge 
of the effects of insulin.  As with other therapeutic advances assessed in this review, the 
failure to establish much effect on hypoglycemia, may be because the expert application 
of these practical skills is limited to relatively few patients. 
Closed loop systems 
In view of the limitations described above then the development of a closed loop system 
in which continuous glucose monitoring is combined with the use of a pump controlled 
by an external computer has major attractions.  It would obviate the need for input from 
the patient apart from filling the insulin reservoir and replacing the sensor and its 
attachment.  The potential for such a device is clearly huge although the expense will 
limit uptake even within the developed world.  
The reader is directed elsewhere for a detailed review of recent approaches.(33)  Most of 
the current work is focussing on devices which incorporate both subcutaneous glucose 
sensing and insulin delivery.  The limitations of sc insulin administration are less 
important when blood glucose flux is relatively low but are challenged during eating or 
exercise.  Thus, much effort is focussed on overnight glucose control.  Some promising 
early data are emerging and investment in the field is now considerable, but closed loop 
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devices remain research tools.  The development of a practical reliable device, even for 
those with hypoglycemic problems remains years away.  
Restoring symptoms 
Programs reversing hypoglycemia unawareness 
The observation that repeated episodes of short-duration, mild hypoglycemia impair  
sympathoadrenal and symptomatic response to subsequent episodes  and contribute to 
HAAF suggested that defects were functional rather than structural.  The implication that 
such impairment might therefore be reversible has been established by different groups in 
experimental settings.(34-36)  What is more relevant is how such approaches work in 
clinical practice.  The essential component reported by the three studies was the 
avoidance of all hypoglycemic episodes for a few weeks.  This required a labour 
intensive approach with frequent, often daily contact between professional and patient, 
blood glucose monitoring and insulin adjustment to prevent episodes, particularly at 
night.  In these relatively short-term studies there was no significant deterioration in 
glycemic control although HbA1c moved higher in all three.  It is not clear whether 
reversal of unawareness can be achieved in all patients or if such benefits are sustained.  
For those who regain symptomatic awareness there is the challenging task of maintaining 
reasonable glycemic control while avoiding relapse due to further hypoglycemic 
episodes.   
In a short report from one of the original centres, 4 of the original 6 patients with 
unawareness were retested 3 years after their reversal program.(37)  Relatively tight 
glycemic control had been maintained, repeated hypoglycemia had generally been 
avoided and symptomatic responses to experimental hypoglycemia, while lower than 
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those measured at the end of the original study, were higher than at baseline. However, 
these are small numbers.  It is noteworthy that no centre appears to have published their 
longterm clinical experience of managing this problem and such reports would be of 
considerable value.  Anecdotally, it is our experience and of others that some individuals 
find it impossible to alter their glucose targets and continue to be subject to severe 
hypoglycemic episodes.  That severe problems with hypoglycemia and unawareness have 
emerged as the main clinical indication for whole pancreas and islet transplantation also 
suggests that hypoglycemia reversal programmes are limited in the degree and duration 
of benefit. 
Specific therapies to prevent or reduce hypoglycemia  
Caffeine/theophylline 
The adenosine antagonists caffeine and theophylline are probably the most studied of 
potential therapeutic agents to reverse or prevent hypoglycemia unawareness.  The 
potential of caffeine was suggested by a study which reported increased catecholamines 
and symptoms during experimental hypoglycemia.(38) Based on this and other studies 
the authors undertook a 3 month clinical trial in patients with Type 1 diabetes and 
demonstrated increased number of symptomatic episodes although there was no 
difference in asymptomatic or severe episodes.(39)  A more recent study involving 
relatively small numbers has reported reduced duration of nocturnal hypoglycemia, 
(Figure 2) (40) as measured by continuous glucose monitoring.  
Theophylline has also been evaluated as a treatment for hypoglycemia unawareness. 
Patients were recruited to a study in which theophylline was given as an intravenous 
infusion during slow fall hypoglycemic clamp.(41)  The rise in cerebral blood flow was 
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prevented and the threshold for the increase in symptoms and epinephrine shifted to a 
higher level although there was no increase in glucagon concentrations.  The same group 
then studied the effect of oral theophylline over 2 weeks and again demonstrated 
increases in symptoms (although not epinephrine) during experimental 
hypoglycemia.(42)   
While these results are of interest, the crucial question is whether these agents protect 
patients from severe episodes during clinical treatment.  In no study were sufficient 
patients treated for long enough to assess the effect on hypoglycemia unawareness or 
rates of severe hypoglycemia.  This is of particular relevance to these agents since they 
reduce cerebral blood flow.  Whilst this might contribute to a more pronounced 
symptomatic response, an unwanted consequence might actually be increased 
vulnerability to severe episodes. 
Modafanil 
The evidence that K ATP channels modulate hypothalamic sensing of hypoglycemia(43) 
and deficient counterregulation,(44) perhaps through effects on GABA (45) presents 
other therapeutic targets.  Modafanil, an agent used in narcolepsy, reduces GABA 
activity perhaps through effects on potassium channels.(46)  The hypothesis that 
inhibition of GABAminergic neurones might augment the sympathoadrenal response has 
been tested in non-diabetic subjects who received a moderate dose of modafanil or 
placebo immediately prior to a slow fall glucose clamp.(47)  There was a modest increase 
in adrenergic symptoms and protection of cognitive function but no effect on epinephrine 
levels.  The authors concluded that modafanil was worthy of further investigation but 
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neither they nor apparently anyone else has since studied patients with diabetes or 
hypoglycemia unawareness. 
The same group has also investigated drugs which modify KATP channels, gliburide (a 
channel closer) and diazoxide (a channel opener).(48)  Immediate delivery of either agent 
to non-diabetic subjects before experimental hypoglycemia had no effect on 
counterregulatory responses although those treated with gliburide, showed some 
preservation of cognitive function compared with diazoxide and placebo.  A further study 
where diazoxide was administered immediately prior to experimental hypoglycemia also 
had no effect on sympathoadrenal responses.(49)  These human data contradict the 
positive effect of potassium channel openers on the hypoglycemic sympathoadrenal 
response observed in rodents for reasons, as yet unclear.  Thus, clinical potential remains 
uncertain and needs further investigation.  
 
Selective serotonin re-uptake inhibitors (SSRIs) 
The use of SSRIs to augment the counterregulatory response has also been explored.(50)  
Early reports actually associated these drugs with hypoglycemia but the authors reasoned 
that blocking serotonin uptake might increase sympathetic outflow.  They demonstrated 
increased sympathoadrenal responses and cortisol concentrations during experimental 
hypoglycemia in non-diabetic subjects although symptoms were unaltered.  These 
observations now need confirming in diabetic subjects and those with unawareness.  
Boosting glucose counterregulation 
A number of human studies in experimental settings have measured the potential of 
pharmacological activation of counterregulatory mechanisms to boost blood glucose 
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levels and so reduce the risk of hypoglycemia, particularly at night.  Alanine may restore 
deficient glucagon responses in individuals with Type 1 diabetes at least in part.(51)  
Nocturnal hypoglycemia can be prevented by oral terbutaline given at bedtime in contrast 
to the relative ineffectiveness of bedtime snacks but at the expense of a higher fasting 
glucose concentration.(52)  The authors commented that finding a dose which could 
reliably prevent nocturnal hypoglycemia without raising fasting glucose concentrations is 
challenging.(53)  
It is noteworthy that as with other potential treatments described above, these small scale 
studies which provide proof of principle have not been followed by larger trials, 
adequately powered and of sufficient duration to measure differences in severe 
hypoglycemia.  It is unclear whether this gap in the literature is related to a perception 
that therapies are ineffective, the difficulty in securing funding or merely the logistics in 
running multicentre trials.   
Type 2 diabetes  
It is beyond the scope of this review to evaluate specific treatments for Type 2 diabetes. 
Montori et al have recently commented (54) that there are few independently funded 
trials which have addressed the effects of glucose lowering therapy using endpoints that 
are relevant to patients.  However some relevant observations can be drawn from the 
recent publication of the ACCORD (55) and ADVANCE (56) trials although more 
detailed information around hypoglycemia will emerge shortly.  The ACCORD trial 
utilised an aggressive glucose control strategy with multiple oral agents and the early use 
of insulin combining both overnight and pre-prandial insulin and aiming for an HbA1c of 
6% or below.  This produced considerable severe hypoglycemia which may have 
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contributed to the adverse outcomes.  In contrast, a less aggressive approach targeting 
fasting glucose by the stepwise addition of oral agents and eventually overnight basal 
insulin produced much less severe hypoglycemia and weight gain with an HbA1c level of 
6%. (Figure 3) (56) 
Conclusions 
The virtual elimination of severe hypoglycemia in the few patients receiving either islet 
or whole pancreas transplants demonstrates vividly, the failure of current treatment to 
reproduce the physiology of the β-cell.  As we approach 100 years of insulin therapy, 
many who strive for tight glycemic control are prevented from achieving these targets by 
the frequently troublesome and occasionally devastating side effect of hypoglycemia.  
Data from clinical trials indicate that insulin analogs, pumps and continuous glucose 
monitoring have generally modest effects in reducing hypoglycemic risk: those who 
appear to gain most benefit are those actively and skilfully engaged in their own diabetes 
self management.  Reversal of hypoglycemia unawareness, at least in part, can be 
achieved within relatively short time-periods and without major deterioration in glycemic 
control although the longterm experience of individuals remains unclear. 
Some of the pathological pathways emerging from animal studies have identified 
potential therapeutic targets but early clinical trials have been unimpressive.  It remains to 
be seen how useful animal models of hypoglycemia will be in identifying specific 
therapies to prevent or reverse hypoglycemia.  Promising pilot work in human studies 
should be followed by adequately powered studies measuring severe hypoglycemia.  It is 
also important that trials, including those sponsored by the pharmaceutical industry use 
similar definitions of hypoglycemia.   
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The closed loop device trials signal a potentially exciting advance as would the 
availability of reliable hypoglycemia alarms but the technology is currently inadequate to 
the task.  
In the short-term, it appears that high quality educational/behavioural interventions offer 
the most cost-effective way of enabling less hypoglycemia without worsening glycemic 
control, particularly as successful graduates of such programs appear best placed to take 
advantage of technological advances.  
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Table 1 Approaches to reducing hypoglycemia in clinical practice 
 
Preventing relative or absolute insulin excess 
 
Training in insulin self management 
Blood glucose awareness training (BGAT) 
 
Insulin analogs 
Continuous subcutaneous insulin infusion 
 
Pancreas transplantation 
Islet Cell Transplantation 
 
Alerting patients to impending hypoglycemia  
 
Hypoglycemia alarms utilising continuous glucose monitoring technology 
 
Restoring symptoms of awareness of hypoglycemia  
 
Hypoglycemia unawareness reversal programs 
 
 
Augmenting glucose counterregulation  
 27
 Indirect 
K ATP channel openers 
Modafanil 
Diazoxide 
Selective serotonin re-uptake inhibitors (SSRIs) 
 
Direct 
Alaninine 
Terbutaline 
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Table 2 Features of hypoglycemia reversal programmes 
 
• Preventing all hypoglycaemic episodes for 3-6 week while keeping glycaemic 
control unaltered 
• Frequent blood glucose monitoring (especially at night) 
• Insulin adjustment of dose and type 
• Labour intensive for patient and clinician 
• Often takes months 
 
 
Figure Legends 
 
Fig. 1. HbA1c and incidence of severe hypoglycaemia (per patient/ preceding year) at 
baseline and at the follow-up examinations in patients with a diabetes duration > 1 year at 
entry, following delivery of an intensified treatment and teaching programme )ITTP) (n = 
necessitating treatment with intravenous glucose or glucagon injection. Figure 
reproduced from (5) with permission 
538). Severe hypoglycaemia was defined as a self-reported episode of hypoglycaemia 
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Fig 2 Total number of hypoglycemic events in 34 individuals with Type 1 diabetes over 3 
months. Biochemical  ?, P=ns, Symptomatic ?  (P < 0.03 caffeine vs. placebo), figure 
reproduced from (39) with permission 
 
Fig 3 Absolute rates of severe hypoglycemia (% of subjects affected during the trial) in 
the 2 glucose arms of the ACCORD and ADVANCE trials. 
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